Profile of entrectinib and its potential in the treatment of ROS1-positive NSCLC: evidence to date
Francesco Facchinetti, Luc Friboulet INSERM U981, Gustave Roussy Cancer Campus, Université Paris Saclay, Villejuif, FranceCorrespondence: Francesco FacchinettiINSERM U981, Gustave Roussy Cancer Campus, 114 Rue Edouard, Villejuif 94800, FranceTel + 33 14 211 5662Email Francesco.Facchinetti...
Guardado en:
| Autores principales: | , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2019
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/86eac883de4548c38cf524c882715cd7 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| Sumario: | Francesco Facchinetti, Luc Friboulet INSERM U981, Gustave Roussy Cancer Campus, Université Paris Saclay, Villejuif, FranceCorrespondence: Francesco FacchinettiINSERM U981, Gustave Roussy Cancer Campus, 114 Rue Edouard, Villejuif 94800, FranceTel + 33 14 211 5662Email Francesco.Facchinetti@gustaveroussy.frAbstract: ROS1 inhibition provides impressive survival benefits in ROS1-rearranged non-small cell lung cancer (NSCLC) patients. Crizotinib is the only tyrosine kinase inhibitor (TKI) approved by both FDA and EMA for the treatment of ROS1-positive lung cancer. In addition, several TKI have been tested with preliminary proofs of success in this oncogene-driven disease, either in the post-crizotinib setting or as first-line targeted agents. Here we present the evidence concerning entrectinib, an ALK/ROS1/NTRK inhibitor developed across different tumor types harboring rearrangements in these genes, in the context of ROS1-driven NSCLC. Of interest, in August 2019 entrectinib was granted by FDA accelerated approval for the treatment of ROS1-rearranged NSCLC, as well as of NTRK-driven solid tumors.Keywords: lung cancer, ROS1, tyrosine kinase inhibitors, entrectinib |
|---|